Translational Research, a subsidiary of Japan-based Shin Nippon Biomedical, has developed an intranasal formulation of granisetron, an agent with antiemetic efficacy, the company reported.
Granisetron is commonly used to reduce side effects of antitumor therapy. In preclinical studies, the new formulation has shown immediate action, equivalent to injection, and high absorbability through nasal mucosa.
Phase I trials will begin within the year, and the company expects to market the new formulation by 2010.
